The generative AI market in drug discovery is expanding rapidly, expected to grow from $0.33 billion in 2026 to $0.86 billion by 2030 with a 27% CAGR. Growth is fueled by rising drug development costs, advances in AI technologies like deep learning, and increased biological data availability. Key trends include AI-driven molecule generation and faster early-stage drug development, with major companies like Bayer, NVIDIA, and Merck leading innovations. The market is also benefiting from more clinical trials and strategic acquisitions, indicating a transformative impact on pharmaceutical R&D and personalized medicine.
Nvidia is set to report earnings on August 26 amid strong market expectations for continued growth. Despite a consistent record of beating estimates, options and technical analysis suggest limited upside potential and a risk of a sharp decline to aro...
Despite a down week in stocks and bonds, the S&P 500 remains within 2% of its all-time high, supported by active dip buyers. Commodities like gold, silver, and crude oil show strong performance as investors shift away from financial assets. Healthcar...
Nvidia plans to increase prices for servers containing its AI chips, including Vera Rubin and Grace Blackwell models, by more than 15% for many of its largest customers. The price hikes will depend on chip generation and memory configurations and are...
JPMorgan's JEPI ETF, known for monthly income via covered calls on large caps, faces competition from BlackRock's BALI ETF. Both charge 0.35% and pay monthly, but BALI offers a higher trailing yield of 7.56% versus JEPI's similar payout and has outpe...
Microsoft reported $331 billion in annual revenue with Azure surpassing $100 billion, growing 41%. Its $678 billion contracted commercial backlog supports recurring revenue from AI and cloud services, fueling a 22% upside price target of $590.43. Des...
